A new Science Advances study identifies TRIM29-dependent degradation as a new level of AKR1B10 control in experimental MASH. The finding adds post-translational regulation to a functional AKR1B10–ACC lipogenic connection demonstrated in human hepatic cells more than a decade ago.

AKR1B10 can now be controlled at the level of protein stability.

That is new.

Its functional connection to hepatic lipogenesis is not.

Ma Z. et al. identify TRIM29 as a direct AKR1B10-binding regulator that promotes its ubiquitination and proteasomal degradation.

In human samples, AKR1B10 was elevated in diseased liver tissue and in serum from patients with MASLD compared with controls. In mice fed a high-fat/high-cholesterol diet, genetic loss of Akr1b10 attenuated steatosis, inflammation and fibrosis.

The study then moved from expression to protein turnover.

Hepatic overexpression of TRIM29 reduced AKR1B10 protein and improved multiple features of experimental MASH. Notably, hepatic Akr1b10 mRNA remained unchanged.

The authors further report that coptisine enhanced the TRIM29–AKR1B10 interaction and promoted AKR1B10 degradation. In hepatic cell models, AKR1B10 protein declined without a corresponding decrease in AKR1B10 mRNA.

The separation between transcript and protein is particularly informative.

In 2008, Ma J. et al. demonstrated in breast cancer cells that AKR1B10 interacts with and stabilizes acetyl-CoA carboxylase-α, ACCα, thereby promoting fatty-acid synthesis.

Seven years later, its functional relevance was extended into human liver biology.

Bitter et al. showed that PXR knockdown increased AKR1B10 mRNA and protein in human hepatic cells. The increase was reproduced after PXR knockdown in primary human hepatocytes.

In low-PXR hepatic cells, ACC protein was approximately 1.6-fold higher despite reduced ACACA mRNA. Silencing AKR1B10 reduced de novo lipogenesis by approximately 20%. When ACC was inhibited with TOFA, the AKR1B10-dependent difference in lipogenesis was essentially lost.

The same study extended the connection to human disease. In histologically classified liver samples, median AKR1B10 mRNA expression was approximately threefold higher in moderate-to-severe NASH, while hepatic PXR protein was reduced by more than half compared with non-NASH liver.

By 2015, AKR1B10 had therefore already been functionally linked to ACC-dependent de novo lipogenesis in human hepatic cells and associated with human steatohepatitis.

That chronology matters.

The new Science Advances paper cites the original 2008 study establishing AKR1B10-mediated stabilization of ACCα. An important hepatic intermediate in that chronology, however, is absent from its reference trail: the 2015 study had already connected AKR1B10 to ACC-dependent de novo lipogenesis in human hepatic cells, reproduced AKR1B10 regulation in primary human hepatocytes, and demonstrated increased AKR1B10 in human NASH.

This distinction also defines what is genuinely new in 2026.

The new work does not establish the hepatic functional relevance of AKR1B10 from scratch. It adds something different: regulation of AKR1B10 itself through TRIM29-dependent protein degradation, together with genetic evidence that loss of Akr1b10 attenuates experimental MASH.

The boundaries remain important. The human findings in the new study establish association, whereas the causal MASH evidence derives from mouse models and the detailed degradation mechanism from cellular and biochemical experiments. PXR was not examined, and the study therefore does not test the previously described PXR–AKR1B10 relationship.

Nor does it establish a complete TRIM29–AKR1B10–ACC–DNL pathway in MASH.

What it establishes is a new control point: AKR1B10 protein stability.

Earlier work established stabilization of ACCα by AKR1B10 and functionally linked AKR1B10 to ACC-dependent de novo lipogenesis in human hepatic cells. The 2026 study moves the regulatory question one level upstream: to the stability of AKR1B10 itself.

The degradation mechanism is new.

The hepatic story had already begun.

References

Ma, Z. et al. TRIM29-dependent AKR1B10 degradation ameliorates MASH. Science Advances 12, eaeb9309 (2026). https://doi.org/10.1126/sciadv.aeb9309

Bitter, A. et al. Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms. Archives of Toxicology 89, 2089-2103 (2015). https://doi.org/10.1007/s00204-014-1348-x

Ma, J. et al. Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. Journal of Biological Chemistry 283, 3418-3423 (2008). https://doi.org/10.1074/jbc.M707650200